Introduction {#s1}
============

Old age is associated with failure to maintain homeostasis resulting in degradation of cellular maintenance and repair processes ([@bib38]) and is the single greatest risk factor for many human diseases including cardiovascular disorders, dementias, diabetes, and most cancers ([@bib31]). Interventions that target specific aging hallmarks have been shown to delay or prevent age-related disorders and extend lifespan in model organisms ([@bib29]). Rapamycin, an FDA-approved drug, which directly inhibits the mechanistic target of rapamycin complex I (mTORC1), is one such intervention that extends lifespan and ameliorates a variety of age-related phenotypes ([@bib27]). In mice, rapamycin extends lifespan when administered beginning at 9 or 20 months of age ([@bib24]), and short-term treatments ranging from 6 to 12 weeks during adulthood have been shown to increase lifespan ([@bib8]), improve cardiac function ([@bib20]; [@bib14]) and restore immune function as measured by vaccine response ([@bib11]). Initial indications suggest that mTORC1 inhibition may also reverse declines in age-related heart function in companion dogs ([@bib51]; [@bib52]), and age-related immune function ([@bib39]; [@bib40]) and skin aging ([@bib13]) in humans.

Periodontal disease is clinically defined by inflammation of the periodontium, the specialized tissue surrounding and supporting the tooth structure, resulting in clinical attachment loss, alveolar (periodontal) bone loss and periodontal pocketing, and pathogenic changes in the oral microbiome ([@bib34]; [@bib35]). Most recent epidemiologic data in the U.S. population suggests that more than 60% of adults aged 65 years and older have periodontitis ([@bib17]; [@bib18]), and diagnosis with periodontal disease is associated with increased risk for other age-related conditions including heart disease, diabetes, and Alzheimer's disease ([@bib23]; [@bib33]; [@bib46]).

Given that periodontal disease shows a similar age-related risk profile as other age-associated diseases ([@bib4]), we predicted that interventions which target biological aging could be effective at treating periodontal disease. Consistent with that hypothesis, aged mice treated with rapamycin have greater levels of periodontal bone than control animals ([@bib3]). In order to further test this idea and to understand potential mechanisms by which mTOR activity influences oral health during aging, we carried out a longitudinal study in which we asked whether transient rapamycin treatment during middle age can impact three clinically defining features of periodontal disease: loss of periodontal bone, inflammation of periodontal tissues, and pathogenic changes to the microbiome. Here we report that 8 weeks of treatment with rapamycin in aged mice is sufficient to regrow periodontal bone, reduce inflammation in both gingival tissue and periodontal bone, and revert the composition of the oral microbiome back toward a more youthful state.

Results {#s2}
=======

In order to understand potential mechanisms by which aging and mTOR activity influence oral health, we carried out two parallel longitudinal studies at two sites in which aged mice were treated with either vehicle control or rapamycin for 8 weeks. NIA-UW mice were housed at the University of Washington and JAX mice were housed at The Jackson Laboratory (see Materials and methods). We used microCT (μCT) imaging to measure the amount of periodontal bone present in the maxilla and mandible of young (6 month), adult (13 month), and old (20 month) mice from the NIA-UW cohort ([Figure 1A](#fig1){ref-type="fig"}). The amount of periodontal bone for the maxilla and mandible of each animal was calculated as the distance from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) for 16 landmarked sites each on the buccal aspect of the maxillary and mandibular periodontium ([Figure 1B](#fig1){ref-type="fig"}). Thus, larger values represent greater bone loss. As expected, there was a significant loss of periodontal bone with age in the NIA-UW cohort ([Figure 2, A to C](#fig2){ref-type="fig"}). Mice treated with rapamycin for 8 weeks had significantly more bone at the end of the treatment period compared to mice that received the control diet (eudragit) ([Figure 2C](#fig2){ref-type="fig"}). To determine whether the increase in periodontal bone upon rapamycin treatment reflects attenuation of bone loss or growth of new bone, we performed μCT imaging on mice before and after treatment in the JAX cohort ([Figure 1A](#fig1){ref-type="fig"}). Old mice randomized into either the eudragit control or rapamycin treatment groups had significantly less periodontal bone than young mice prior to the treatment period ([Figure 2F](#fig2){ref-type="fig"}). After 8 weeks, the rapamycin treated mice had significantly more periodontal bone compared to eudragit controls and also compared to the pre-treatment levels for the same animals ([Figure 2](#fig2){ref-type="fig"}, D to F). The presence of new bone following rapamycin treatment can be observed by comparison of μCT images from the same animals before and after treatment ([Figure 2, D and E](#fig2){ref-type="fig"}).

![Cross-institution experimental design and assay for measuring periodontal bone loss.\
(**A**) The NIA-UW colonies were received directly from the NIA Aged Rodent Colony at 4, 11, and 18 months, then acclimated for two months within the UW facilities (ARCF) until they reached 6 (Young), 13 (Adult), and 20 months (Old). The Young and Adult cohorts were harvested for oral tissues and microbiome. The Old cohorts were randomized and either given Eudragit or 42ppm eRAPA within the food for 8 weeks. For the JAX colonies, an initial microCT image was taken prior to the 8 week treatment and then a final microCT before harvest. All animals were harvested at the end of 8 weeks, \~22 months old. (**B**) Representative image of a mandible is shown. Periodontal bone loss was measured as distance from the cementoenamel junction (CEJ, white arrows) to the alveolar bone crest (ABC, orange arrows) on 16 predetermined landmarks on the buccal aspect of maxillary and mandibular periodontium. The CEJ-ABC distances were totaled for each mouse.](elife-54318-fig1){#fig1}

![Rapamycin reverses age-associated periodontal bone loss (NIA-UW and JAX).\
(**A and B**) Representative images of NIA-UW (**A**) maxillary and (**B**) mandibular teeth of Young, Old, and Old treated with 42ppm eRAPA (rapamycin) revealing age-associated periodontal bone loss. 8 weeks of rapamycin attenuated periodontal bone loss. (**C**) Box-and-whiskers plots shows median, 25^th^ and 75^th^ percentile with whiskers at the 5^th^ and 95^th^ percentile. Statistical analysis was completed using unpaired t-test, with p-values \<0.05 were considered statistically significant. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005 (**D and E**) Representative images of the (**D**) maxillary and (**E**) mandibular teeth from the same animal in the JAX cohort before treatment (labeled Old) and after 8 weeks of 42ppm eRAPA (labeled Old+Rapamycin). On both the maxilla and mandible, there is periodontal bone loss around and in-between the molars, but after 8 weeks of 42ppm eRAPA the bone loss is reversed. White arrowheads indicate areas of bone loss and bone loss reversal (**F**) Box-and-whiskers plots shows median, 25^th^ and 75^th^ percentile with whiskers at the 5^th^ and 95^th^ percentile. Longitudinal comparison was completed with the same animal at baseline or after 8 weeks with either eudragit (control) or 42ppm eRAPA (rapamycin). Statistical analysis was completed using paired t-test, with p-values \<0.05 were considered statistically significant. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005.](elife-54318-fig2){#fig2}

Normal bone homeostasis results from a balance between new bone growth and bone resorption, which is reflected by the ratio of RANKL (receptor-activator of nuclear factor-κB ligand) to OPG (osteoprotegerin), and dysregulation of this balance contributes to bone loss in periodontitis ([@bib15]). Consistent with bone loss during aging, we detected significantly greater levels of RANKL in old animals of both cohorts compared to young animals ([Figure 3A and B](#fig3){ref-type="fig"}). OPG levels remained relatively stable, resulting in an increase in the RANKL:OPG ratio indicative of bone resorption exceeding bone formation ([Figure 3C](#fig3){ref-type="fig"}). These age-associated defects in bone homeostasis were suppressed by eight weeks of rapamycin treatment ([Figure 3](#fig3){ref-type="fig"}). In addition to increased RANKL:OPG ratio, a significant increase in TRAP^+^ cells was also observed in periodontal bone with age ([Figure 3D and E](#fig3){ref-type="fig"}). TRAP (tartrate-resistant acid phosphatase) is a histochemical marker of bone resorbing osteoclasts ([@bib25]; [@bib7]). Rapamycin treatment for eight weeks also decreased TRAP^+^ cells. Together, our data indicate that rapamycin reverses periodontal bone loss in the aging murine oral cavity at least in part through inhibition of bone resorption.

![Rapamycin attenuates age-associated increase in RANKL expression and TRAP+ cells in periodontal bone.\
(**A and B**) RANKL and OPG expression was determined by western blot analysis of total lysates from the periodontal bone of aged animals (Young, Adult, and Old) and Old animals treated for 8 weeks with 42ppm rapamycin (eRAPA). The periodontal bone within both the NIA-UW and JAX Colonies showed an increased expression of RANKL while 8 weeks of rapamycin treatment ameliorated the increased RANKL expression. Each lane represents individual periodontal bone samples. (**C**) Quantification of RANKL/OPG of the NIA-UW western blot analysis. (**D**) Representative histological sections of the alveolar bone furcation that have undergone TRAP azo-dye staining with FastGreen counterstain. (**E**) Enumeration of TRAP^+^ cells within the periodontal bone from two-independent observers reveals an increase number of TRAP^+^ cells with age and diminishes with rapamycin treatment. Statistical analysis was completed with unpaired t-test, with significance set to p\<0.05. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.005.](elife-54318-fig3){#fig3}

Along with bone loss, gingival inflammation is a defining feature of periodontal disease. Aging is also associated with chronic accumulation of pro-inflammatory factors, a collective term referred to as inflammaging ([@bib12]; [@bib22]; [@bib21]; [@bib16]). The nuclear factor-κB (NF-κB) is a hub of immune and inflammatory response activated both during normal aging and as a consequence of periodontal disease ([@bib6]; [@bib2]; [@bib1]; [@bib37]). We first evaluated the NF-κB hub through NF-κB p65 and IκBα expressions levels. The NF-κB heterodimer consists of RelA (or p65) and p50. IκBα functions as a negative regulator of NF-κB by sequestering it in the cytoplasm. Degradation of IκBα or phosphorylated-IκBα leads to nuclear localization of NF-κB subunits which induce expression of target inflammatory genes, such as TNF-α and IL-1β ([@bib37]). In both the gingival tissue and periodontal bone, there was an increase in p65 expression with corresponding decrease of IκBα levels, indicating an age-associated increase in NF-κB inflammatory signaling in the periodontium ([Figure 4, A and B](#fig4){ref-type="fig"}). Eight weeks of rapamycin treatment was sufficient to reverse these changes. We also examined the levels of inflammatory cytokines in the oral cavity associated with normative aging and rapamycin treatment in mice. Consistent with the increase in NF-κB signaling, we found elevated expression of several cytokines in both the gingival tissue and the periodontal bone ([Figure 4, E and F](#fig4){ref-type="fig"}). Eight weeks of rapamycin treatment reversed most age-associated chemokine and cytokine changes in both the gingival tissue and periodontal bone. Thus, transient treatment with rapamycin during middle-age can largely restore a youthful inflammatory state in both the gingiva and periodontal bone of mice ([@bib54]).

![Rapamycin alters increased NF-κB expression and inflammatory cytokine profiles in periodontium.\
NF-κB p65 and IκBα expression was determined by western blot analysis of total lysates from the gingiva (**A,C**) and periodontal bone (**B,D**) of control animals (Young, Adult, and Old) and Old animals treated for 8 weeks with rapamycin (42ppm eRAPA). GAPDH was used a loading control. Both in the aging gingiva and periodontal bone, there is an overall increased expression of NF-κB p65 with corresponding alteration of IκBα or p-IκBα. 8 weeks of 42ppm eRAPA treatment attenuates the changes seen with age. For the gingiva, each lane represents gingiva from animals co-housed (n = 2), and each lane for the periodontal bone western blot represents individual animals. (**E and F**) Protein expression levels of mouse cytokines and chemokines was determined by a spotted nitrocellulose membrane assay (Proteome Profiler Mouse, R and D Systems) by loading pooled samples from (**E**) gingiva and (**F**) periodontal bone of Young and Old (Control, Eudragit), and Old animals treated for 8 weeks with rapamycin (42ppm eRAPA). Data are shown per manufacture's protocol, with fold-change relative to Young (Set to 1), expressed as mean ± SEM. All changes shown are statistically significant (p\<0.05). CXCL16 and MCSF expression levels in (**E**) were not statistically significant.](elife-54318-fig4){#fig4}

Dysbiotic shifts in the oral microbiome are thought to play a significant role in the progression of periodontal disease in humans. We and others have previously shown that rapamycin treatment can remodel the gut microbiome in mice ([@bib8]; [@bib28]; [@bib26]); however, the effect of rapamycin on the oral microbiome has not been explored. Therefore, we sought to evaluate effects of rapamycin on the aged oral microbiome using 16S rRNA gene sequencing and Amplicon Sequence Variant (ASV) analysis approach. Examination of the alpha diversity of the oral cavity illustrated a significant increase in species richness during aging that rapamycin attenuated ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Among the most notable alterations in taxonomic abundance between groups was the reduction of *Bacteroidetes* phylum in the rapamycin-treated old animals ([Figure 5B](#fig5){ref-type="fig"}). When pooled across sites, no significant difference was observed between levels of *Bacteroidete*s in untreated young animals and old animals treated with rapamycin. Old animals treated with rapamycin in the JAX cohort had even lower levels of *Bacteroidetes* than young untreated mice (p\<0.05), whereas in the UW cohort rapamycin treatment lowered the levels of *Bacteroidetes* to the level of the young mice ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The *Bacteroidetes* phylum consists of over 7000 different species ([@bib49]) and includes bacteria associated with human periodontal disease such as *Porphyromonas gingivalis, Treponema denticola,* and *Bacteroides forsythus* ([@bib53]; [@bib50]; [@bib48]). Further, both the *Firmicutes* and *Proteobacteria* phyla also showed a significant difference that was age dependent ([Figure 5B](#fig5){ref-type="fig"}) but was not significantly altered by rapamycin treatment. In order to assess whether rapamycin is shifting the composition back towards a youthful state, we evaluated the beta diversity using weighted UniFrac distances. We discovered a significant separation of the oral microbiome between old control and old rapamycin-treated animals, while no significant differences were observed between young mice and old rapamycin-treated mice ([Figure 5C](#fig5){ref-type="fig"}). Overall, we observed no significant differences in alpha diversity, beta diversity, nor relative taxonomic abundance between young untreated mice and old mice treated with rapamycin, suggesting an eight-week treatment with rapamycin reverted the old oral microbiome to a more youthful state. This observation is further supported when analysis of the samples is performed independently by facility (UW-NIA or JAX) ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Despite differences in animal facility and diet composition, no batch effect was detected when comparing the JAX and NIA-UW cohorts (PERMANOVA, nperm = 999, p=0.34) ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}).

![Rapamycin shifts aged oral microbiome towards young oral microbiome.\
(**A**) Alpha diversity for all samples reveal significant differences between young (Y) and old (O) mice without rapamycin treatment (p\<0.05). (**B**) Phylum level abundance using normalized agglomerated data show significant difference for the *Bacteroidetes* (p\<0.001) in old (O) mice and old mice with rapamycin treatment (R) for all samples. Also, significant changes are observed in the *Firmicutes* (p\<0.05) and *Proteobacteria* phylum (p\<0.05, p\<0.01) that is age and treatment dependent. (**C**) Principal coordinate analysis using weighted Unifrac distances reveal beta diversity in the rapamycin-treated old (R) groups clustered with the young (Y). (**C**, inner panel) A significant separation between old (O) and rapamycin-treated old (R) groups (p\<0.01; Axis 1, 70.3%) was observed, but no significant difference between young (Y) and rapamycin-treated old (R) groups was observed. \*p\<0.05, \*\*p\<0.01,\*\*\*p\<0.001.](elife-54318-fig5){#fig5}

Discussion {#s3}
==========

Taken together, our data demonstrate that a short-term treatment with rapamycin in aged mice is sufficient to reverse three clinically defining features of periodontal disease: periodontal bone loss, periodontal inflammation, and pathogenic changes to the oral microbiome. This adds further support for the Geroscience Hypothesis, which posits that any intervention which targets the biological aging process will simultaneously delay multiple age-related diseases and functional declines ([@bib30]; [@bib47]). To the best of our knowledge, this is the first report of rejuvenation in the aged oral cavity.

This work suggests several interesting questions that it will be important to evaluate in future studies. One such question is whether the effects of rapamycin on the aged periodontium will persist after the treatment period or will rapidly revert back to the aged state. Improvements in age-related cardiac function associated with a similar rapamycin treatment regimen have been found to persist for at least eight weeks following cessation of treatment ([@bib45]), and it will be of interest to determine whether similar outcomes are observed for improvements in oral health. It will also be important in future studies to determine whether these effects are mediated through local inhibition of mTORC1 in the gingiva and periodontal bone or through systemic effects on immune function or other tissues. Likewise, it will be of interest to understand whether additional features of oral health that are known to decline with age, such as salivary function, are improved by rapamycin treatment. Finally, these results suggest the intriguing likelihood that additional geroscience interventions, such clearance of senescent cells, may phenocopy the effects of rapamycin in this context. Such interventions could pave the way for the first effective treatments to reverse periodontal disease and improve oral health in the elderly.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                              Designation                                                  Source or reference                                                  Identifiers                                                              Additional\
  (species) or resource                                                                                                                                                                                                                                 information
  ------------------------------------------ ------------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------
  Strain, strain background(*M. musculus*)   C57BL/6NIA                                                   NIA Aged Rodent Colony                                                                                                                        PMID:[27549339](https://www.ncbi.nlm.nih.gov/pubmed/27549339)

  Strain, strain background(*M. musculus*)   C57BL/6J                                                     Jackson Laboratory                                                   RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Chemical compound, drug                    Rapamycin                                                    Rapamycin Holdings                                                                                                                            Amount based upon active rapamycin content to provide 42 parts per million concentration in chow.

  Chemical compound, drug                    Eudragit                                                     Rapamycin Holdings                                                                                                                            

  Chemical compound, drug                    RIPA Lysis and Extraction Buffer                             ThermoFisher\                                                        Cat\#: 89901                                                             
                                                                                                          Scientific                                                                                                                                    

  Chemical compound, drug                    HALT Protease\                                               ThermoFisher\                                                        Cat\#: 78438                                                             
                                             Inhibitor Cocktail                                           Scientific                                                                                                                                    

  Chemical compound, drug                    HALT Phosphatase Inhibitor Cocktail                          ThermoFisher\                                                        Cat\#: 78420                                                             
                                                                                                          Scientific                                                                                                                                    

  Chemical compound, drug                    Restore Plus Stripping Buffer                                Thermfisher Scientific                                               Cat\#: 46430                                                             

  Antibody                                   anti -NFkBp65(Rabbit Monoclonal)                             Cell Signaling                                                       Cat\#: 8242                                                              WB (1:1000)

  Antibody                                   anti-phospho-IκBα (Mouse monoclonal)                         Santa Cruz\                                                          Cat\#: sc8404                                                            WB (1:1000)
                                                                                                          Biotechnology                                                                                                                                 

  Antibody                                   Anti- IκBα\                                                  Abcam                                                                Cat\#: 32518                                                             WB (1:1000)
                                             (Rabbit Monoclonal)                                                                                                                                                                                        

  Antibody                                   anti-GAPDH\                                                  Cell Signaling                                                       Cat\#: 5174                                                              WB (1:1000)
                                             (Rabbit monoclonal)                                                                                                                                                                                        

  Antibody                                   anti-RANKL\                                                  Santa Cruz Biotechnology                                             Cat\#: sc377079                                                          WB (1:1000)
                                             (Mouse monoclonal)                                                                                                                                                                                         

  Antibody                                   anti-OPG\                                                    R and D Systems                                                      AF459                                                                    WB (1:1000)
                                             (Goat polyclonal)                                                                                                                                                                                          

  Antibody                                   anti-IgGκ\                                                   Santa Cruz Biotechnology                                             Cat\#: sc516102                                                          WB (1:10000)
                                             (Mouse monoclonal)                                                                                                                                                                                         

  Antibody                                   anti-rabbit IgG (Donkey polyclonal)                          Thermo Fisher Scientific                                             Cat\#: 31458                                                             WB (1:10000)

  Antibody                                   anti-goat IgG\                                               Abcam                                                                Cat\#: ab97110                                                           WB (1:10000)
                                             (Donkey polyclonal)                                                                                                                                                                                        

  Commercial assay, kit                      Proteome Profiler Mouse XL Cytokine Array                    R and D Systems                                                      Cat\#: ARY028                                                            

  Commercial assay, kit                      Acid Phosphatase, Leukocyte (TRAP) Kit                       Millipore Sigma                                                      Cat\#: 387A-1KT                                                          

  Commercial assay, kit                      QIAamp DNA Microbiome Kit                                    Qiagen                                                               Cat\#: 51704                                                             

  Commercial assay, kit                      DNA Clean and Concentrator Kit                               Zymo Research                                                        Cat\#: D4014                                                             

  Commercial assay, kit                      KAPA HiFi HotStart ReadyMix                                  KAPA Biosystems                                                      Cat\#: KK2601                                                            

  Commercial assay, kit                      Nextera XT Index Kit V2                                      Illumina                                                             Set A: FC-131--2001\                                                     
                                                                                                                                                                               Set D: FC-131--2004                                                      

  Commercial assay, kit                      AMPure XP Beads                                              Agencourt                                                            A63881                                                                   

  Commercial assay, kit                      SequalPrep Normalization Kit                                 Invitrogen                                                           A1051001                                                                 

  Commercial assay, kit                      TapeStation 4200 High Sensitivity D1000 assay                Agilent Technologies                                                 G2991AA                                                                  

  Commercial assay, kit                      Tapestation\                                                 Agilent Technologies                                                 5067--5585                                                               
                                             Reagents                                                                                                                                                                                                   

  Commercial assay, kit                      High Sensitivity D1000 ScreenTape                            Agilent Technologies                                                 5067--5584                                                               

  Commercial assay, kit                      Qubit High Sensitivity dsDNA assay                           ThermoFisher Scientific                                              Q32854                                                                   

  Commercial assay, kit                      MiSeq Reagent Kit v3 (600 cycle)                             Illumina                                                             Cat\#: MS-102--3003                                                      

  Commercial assay, kit                      PhiX Control Kit v3                                          Illumina                                                             Cat\#: FC-110--3001                                                      

  Software, Algorithm                        Qiime2                                                       <https://qiime2.org/>                                                V.2019.1                                                                 

  Software, Algorithm                        DADA2 Package                                                PMID:[27214047](https://www.ncbi.nlm.nih.gov/pubmed/27214047)                                                                                 

  Software, Algorithm                        Human Oral Microbiome Database (HOMD)                        [Homd.org](http://homd.org/)\                                                                                                                 v\. 15.1
                                                                                                          PMID:[30534599](https://www.ncbi.nlm.nih.gov/pubmed/30534599)                                                                                 

  Software, Algorithm                        R-studio                                                     <https://rstudio.com/>                                               RRID:[SCR_000432](https://scicrunch.org/resolver/SCR_000432)             Version 3.5.3

  Software, Algorithm                        Phyloseq                                                     PMID:[23630581](https://www.ncbi.nlm.nih.gov/pubmed/23630581)        RRID:[SCR_013080](https://scicrunch.org/resolver/SCR_013080)             

  Software, Algorithm                        Clustvis                                                     PMID:[25969447](https://www.ncbi.nlm.nih.gov/pubmed/25969447)        RRID:[SCR_017133](https://scicrunch.org/resolver/SCR_017133)             

  Software, Algorithm                        Ggplot2                                                      <https://www.springer.com/gp/book/9780387981413>                     RRID:[SCR_014601](https://scicrunch.org/resolver/SCR_014601)             <https://www.springer.com/gp/book/9780387981413>

  Software, Algorithm                        Ampvis2                                                      <http://dx.doi.org/10.1101/299537v1>                                                                                                          

  Software, Algorithm                        vegan                                                        <https://cran.r-project.org>, <https://github.com/vegandevs/vegan>   RRID:[SCR_011950](https://scicrunch.org/resolver/SCR_011950)             

  Software, Algorithm                        Ade4                                                         <https://www.jstatsoft.org/article/view/v086i01>                                                                                              

  Software, Algorithm                        Bioinformatic scripts and microbiome data used in analysis   This paper                                                                                                                                    <https://github.com/kkerns85/Rapamycin_rejuvenates_oral_health_in_aging_mice.git>.

  Software, Algorithm                        R Markdown                                                   This paper                                                                                                                                    <https://rpubs.com/kkerns85/Rapamycin_Rmrkdown>

  Software, Algorithm                        Graphpad Prism                                               Graphpad ([graphpad.com](http://graphpad.com/))                      RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)             Version 8.4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animal studies {#s4-1}
--------------

To enhance rigor and reproducibility, experiments were performed on two different cohorts housed at two sites: the University of Washington in Seattle, WA and the Jackson Laboratory in Bar Harbor, ME. To examine the impact of rapamycin on the periodontium during normative aging, we designed a cross institutional study between the University of Washington (UW) and the Jackson Laboratory (JAX) ([Figure 1A](#fig1){ref-type="fig"}). The UW cohorts of C57BL/6Nia (hereafter termed NIA-UW Colony) were received directly from the National Institute on Aging (NIA) Aged Rodent Colony and acclimated within the UW facilities. The JAX cohorts of C57BL/6J (hereafter termed JAX Colony) were born and raised within the JAX facilities. We then treated mice at both sites with encapsulated rapamycin (eRAPA) in the diet at 42ppm, which has been shown to significantly increase lifespan of UMHET3 and C57BL6/J mice ([@bib43]; [@bib55]), or control food (eudragit). All data are from female mice, which have previously been found to have greater increases in lifespan and some health metrics compared to male mice at this dose of rapamycin ([@bib43]; [@bib55]). For the NIA-UW colonies, five young, five adult, and 20 old (10 eudragit and 10 rapamycin) animals were utilized. While for the JAX colonies a total of 13 young and 26 old (13 eudragit and 13 rapamycin) animals were used. For this study, young, adult, and old mice were 6, 13, and 20 months of age, respectively.

Seattle, WA {#s4-2}
-----------

Twenty NIA-UW mice (10 on eudragit, 10 on rapamycin) received assigned diet treatments at 20 months of age, lasting for 8 weeks, along with five young and five adult mice as normative aging controls. Animals were housed individually in Allentown NexGen Caging (Allentown, Allentown, NJ) containing corncob bedding and nestlets. Mice were fed irradiated Picolab Rodent Diet 20 \#5053 (Lab Diet, St. Louis, MO). Animals were maintained in a specific pathogen free facility within a *Helicobacter spp.-*free room. Mice were housed in groups and inspected daily. National Guidelines for the Care and Use of Animals and the IACUC guidelines were followed.

Bar Harbor, ME {#s4-3}
--------------

All methods are in accordance with The Jackson Laboratory Institutional Animal Care and Use Committee (IACUC)-approved protocols. Animals were fed standard Lab Diet 6% 5K52 with eRapa at 42 mg/kg/day or control. Animals had ad libitum access to food and water throughout the study. Animals were checked daily, and once per week the food was topped off. Animals were housed at 3--5 animals per cage.

A cohort of mice were transferred into the JAX Center for Biometric Analysis and brought into the imaging suite in groups of 10 mice per scan group. Prior to scanning, the weight of each mouse was recorded and anesthesia induced with 2--3% isoflurane. The mice were then placed in a prone position in the CT scanner and kept anesthetized for the duration of the scan with an isoflurane level of 1.2--1.5%. A whole head scan was performed with bone mineral density phantoms included on the specimen positioning bed. After the CT scan, the mouse was placed in a warmed isolation cage and allowed to fully recover from the anesthesia. At the end of the imaging session, the cohort was returned to animal housing facility.

Animal experimentation was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols (\#4359--01) of the University of Washington and (\#06005-A24) of the Jackson Laboratory.

Encapsulated rapamycin feeding {#s4-4}
------------------------------

Encapsulated rapamycin (eRAPA) was obtained from Rapamycin Holdings, Inc. Food pellets were ground and mixed with encapsulated rapamycin at 42ppm. 300 ml of 1% agar melted in sterile water, and 200 ml of sterile distilled water were added per kilogram of powdered chow in order to make pellets. Pellets were stored at −20°C until use. Control food contained the same concentration of agar and encapsulated material (eudragit) without rapamycin at the concentration that matched the rapamycin chow. Eudragit is the encapsulation material used in eRAPA and is a copolymer derived from esters of acrylic and methacrylic acids. Eudragit without rapamycin was thus added to the regular chow at 42 ppm as a vehicle control.

Micro-computed tomography (μCT) analysis {#s4-5}
----------------------------------------

### Seattle Children's Research Institute and Friday Harbor Lab imaging parameter and processing {#s4-5-1}

NIA-UW samples were scanned in a Skyscan 1076 and 1173 microCT system at the Small Animal Tomographic Analysis Facility (SANTA) at Seattle Children's Research Institute and Friday Harbor Laboratories at the University of Washington. Resolutions were 8--18 μm with following settings: 5 kV, 179μA, 360 ms exposure, 0.5 AI filter, 0.7° rotation step, and 3-frame averaging. Raw scan data were reconstructed with NRecon 1.6.9, and three-dimensional (3D) renderings were generated with Drishti 2.7 ([@bib36]). For periodontal bone loss, 3D rendered images were randomized and landmarked by independent observers. Periodontal bone loss was measured as distance from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) on 16 predetermined landmarks on the buccal aspect of maxillary and mandibular periodontium. The CEJ-ABC distances were totaled for each mouse through the Drishti software, and means calculated. The analysis was completed by 3--4 independent observers.

### Jackson Laboratory (JAX) imaging parameter and processing {#s4-5-2}

The mouse is scanned in a Perkin-Elmer Quantum GX in vivo Micro-CT tomograph. Resolutions were 17--50 microns with the following settings: 55 kV, 145 μA, 4 min exposure over 360 degrees rotation. The native Perkin-Elmer Viewer VOX image files are converted to Drishti Volume Exploration and Presentation Tool NetCDF format volumes using custom code specific for this study ([@bib36]).

Western blot and proteome profile analysis {#s4-6}
------------------------------------------

For protein analysis by western blot, gingival tissue and alveolar bone was dissected. Total cellular proteins were extracted in RIPA Lysis and Extraction Buffer (Thermo Scientific, MA, USA) and EDTA-free Halt protease and phosphatase inhibitor cocktail included to prevent protein degradation during extraction process. Gingival tissue was pooled from co-housed animals and bone samples were from single specimens. Protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo Scientific). 10--20 μg of total protein was separated by SDS-PAGE on 10% or 12% (w/v) polyacrylamide gel, then transferred to PVDF membrane using Trans-Blot Turbo Transfer System (Bio-Rad, CA, USA). Antibodies to NF-κB p65 (D14E12) XP (8242, Cell Signaling Technology), phospho-IκBα (B-9, Santa Cruz), IκBα (32518, Abcam), GAPDH (D16H11) XP (5174, Cell Signaling Technology), RANKL (G-1, sc377079, Santa Cruz), and Mouse OPG (R and D Systems, AF459) were used to probe the membrane. Dependent upon the strength of the antibody-dependent signal, either the membranes were stripped with Restore Plus Western Blot Stripping Buffer and reprobed for total antibody, or duplicate gels were run and separate blots probed.

Analysis of the cytokine proteome was completed using a Mouse XL Cytokine Array Kit (R and D Systems, Bio-Techne Corporation, MN, USA). Gingiva and alveolar bone samples were individually pooled, protein concentration determined by Pierce BCA Assay Kit and 200 μg of protein lysate loaded. Detection and imaging were performed using ChemiDoc XRS+ (Biorad, USA) and Image Lab Software (Biorad, USA). Data analysis was completed per the manufacture's protocol.

Histology {#s4-7}
---------

Tissues were fixed in Bouin's solution, and demineralized in AFS (acetic acid, formaldehyde, sodium chloride). Mandibles were processed and embedded in paraffin. Serial sections of 5 μm thickness were collected in the coronal (buccal-lingual) plane. Sections were stained for tartrate-resistant acid phosphatase (TRAP) to examine osteoclast activity and numbers (Sigma-Aldrich Kit, St. Louis, MO, USA), and Fast Green counterstaining and examined with a Nikon Eclipse 90i Advanced Research Scope. Representative images (40x) were taken of the alveolar bone furcation.

Microbiome analysis {#s4-8}
-------------------

### DNA extraction {#s4-8-1}

Mandible samples were cryogrinded and homogenized using bead-beating tubes and ceramic beads. Bacterial genomic DNA was extracted using the QIAamp DNA Microbiome Kit (Qiagen, Hilden, Germany) and further purified and concentrated using DNA Clean and Concentrator Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's protocol, then stored at −80 °C until all samples were collected.

Sequencing {#s4-9}
----------

The V3-V4 variable region of the 16 s ribosomal RNA gene was amplified using gene-specific primers with Illumina adapter overhang sequences (5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3' and 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3'). Each reaction mixture contained 2.5 µl of genomic DNA, 5 µl of each 1 µM primer, and 12.5 µl of KAPA HiFi HotStart ReadyMix. Amplicon PCR was carried out as follows: denaturation at 95°C for 3 min, 35--40 cycles at 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, followed by a final extension step at 72°C for 5 min. PCR products were verified using gel electrophoresis (1% agarose gel) and cleaned with AMPure XP beads (Agencourt, Beckman Coulter Inc, Pasadena, CA, USA). Amplicons were then indexed using the Nextera XT Index Kit V2 set A and set D (Illumina) and purified again with AMPure XP beads to remove low molecular weight primers and primer-dimer sequences. DNA concentrations were concentration of 1--2 nM using the SequalPrep Normalization Kit (Invitrogen). Samples were pooled into a single library which was analyzed using the TapeStation 4200 High Sensitivity D1000 assay (Agilent Technologies, Waldbronn, Germany) and Qubit High Sensitivity dsDNA assay (Thermo Fischer Scientific) to assess DNA quality and quantity. The final pooled library was then loaded on to an Illumina MiSeq sequencer with 10% PhiX spike, which served as an internal control to balance for possible low diversity and base bias present in the 16S amplicon samples, and was run for 478 cycles and generated a total of 5.68 million paired-end reads (2 × 239 bp).

Bioinformatics {#s4-10}
--------------

Raw paired-end sequences were imported in to Qiime2 (v. 2019.1) and were trimmed by 15 nt from the 5' end and truncated to 239 nt for the 3' end for both the forward and reverse reads respectively. The trimmed reads were then demultiplexed and denoised using the DADA2 package ([@bib10]). Forward reads were only used in our analysis. Taxonomy was then assigned using the feature-classifier suite trained on the Human Oral Microbiome Database (HOMD v. 15.1) ([@bib19]). Samples were then filtered for taxonomic contaminants excluded samples with less than 10,000 reads. Alpha and Beta diversity as well as other analysis were done in R-Studio using the Phyloseq ([@bib41]) Clustvis ([@bib42]), ggplot2 ([@bib54]), ampvis2 ([@bib5]), vegan ([@bib44]), ade4 ([@bib9]) packages as part of the R suite.

Taxonomy filtered from samples was determined by analysis of kit controls with no template and zymo sequencing controls of known diversity and abundance in the QIAamp DNA Microbiome Kit (Qiagen, Hilden, Germany) and the DNA Clean and Concentrator Kit (Zymo Research). The following taxonomic assignments were removed as part of the dada2 workflow ([@bib10]): Unassigned, Cyanobacteria, acidovorans, pestis, coli, flavescens, sakazakii, durans, diminuta, anthropi, monocytogenes, parasanquinis_clade_411, otitidis, subtilis, aeruginosa, fermentum.

Statistical analysis {#s4-11}
--------------------

Results for μCT analysis, including measurements, quantitative histology, proteome analysis are expressed as mean ± standard error of mean (SEM). Data were analyzed where appropriate using Student's t-test or paired t-test (comparing two groups only), or one-way analysis of variance (ANOVA) with post-hoc Tukey test for multiple comparisons, where p-values\<0.05 were considered statistically significant. Statistical analysis was completed GraphPad Prism 8.00 (Graphpad, Software, La Jolla, CA, USA). For the 16 s rRNA sequencing, to identify statistically significant differences among agglomerated and normalized amplicon sequence variants (ASV) between samples as well as differences in alpha and beta diversity measures, we applied both the unpaired Wilcoxon rank-sum test as well as the two-tailed paired t-test -- both with a 95% confidence interval (α = 0.05). Alpha diversity was assessed measuring Shannon, Chao1, Observed (ASV), and Fisher diversity measures. Beta diversity was measured using weighted Unifrac distances. Statistical analysis for the microbiome analysis was completed in R (v. 3.5.3).

Data and materials availability {#s4-12}
-------------------------------

All data used in the development of this manuscript and the supplemental material are available in the manuscript or the supplemental materials or upon request. Bioinformatic scripts and microbiome data used in the analysis and generation of figures for this manuscript are available on the McLean Lab GitHub repository: <https://github.com/kkerns85/Rapamycin_rejuvenates_oral_health_in_aging_mice.git> ([@bib32]; copy archived at <https://github.com/elifesciences-publications/Rapamycin_rejuvenates_oral_health_in_aging_mice>). In addition, a web version of the R Markdown is available on Rpubs: <https://rpubs.com/kkerns85/Rapamycin_Rmrkdown>. The V4-16S rDNA sequences in raw format, prior to post-processing and data analysis, have been deposited at the European Nucleotide Archive (ENA) under study accession no. PRJEB35672.
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Decision letter

Galvan

Veronica

Reviewing Editor

UT Health San Antonio

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your work entitled \"Rapamycin rejuvenates oral health in aging mice\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed as outlined below:

Reviewer \#1:

This manuscript reports studies focused on the role of mTOR activity on age-associated periodontal bone loss and gingival inflammation, and the impact of mTOR attenuation with rapamycin on these features of oral cavity aging. The data presented are robust, provide important insights into the mechanisms of oral cavity aging and have substantial translational implications. No major deficiencies are noted.

Reviewer \#2:

In this study, An and colleagues examine the effect of a relatively short-term (\~2 months) rapamycin treatment on the periodontal health of aged mice. To assess periodontal health, the authors use complementary methods including microCT and microbiome analysis using 16S sequencing. The authors show that short-term rapamycin treatment improves a number of periodontal health parameters, and may thus have previously uncharted benefits in this aspect of age-related decline. The study uses 2 cohorts of mice at 2 independent sites (JAX and UW), which is unusual and very much strengthens the conclusions.

I have a few comments that I believe can be mostly addressed textually, which will improve the clarity of the report, and help improve future reproducibility of analysis.

1\) The authors mention \"animals\" at both sites but do not specify the sex of the animals. Since a number of age-related phenotypes, including some rapamycin-related phenotypes, have been shown to be sex-dimorphic, it is critical to specify which sex was used for each cohort, at least in the Materials and methods section.

2\) In this study, rapamycin is delivered through supplementation of diet, and the authors mention that the control chow is reinforced with \"Eudragit\". This reviewer thus assumes that this is to address potential concerns with regular chow diet as a control? It would be extremely helpful to explain the choice of Eudragit (as opposed to normal chow diet) in the main text or Materials and methods.

3\) In their microbiome analysis, the authors mention significance between old control vs. treated (with regards to Figure 5), and no significance between young and old treated. What about young vs. old? Some of the rapa-induced changes look like they may \"overcorrect\", which should be explicitly discussed in the text as a potential caveat.

4\) The authors show both microbiome analysis from combined JAX and UW mice in the main figures and a separated analysis in the supplement. Since there are visible specificities in the supplement based on cohort, did the authors have to apply batch-correction of any sort? It would be great to specify analytical parameters, including batch inclusion (or why it was not warranted) in the Materials and methods.

5\) Could the authors speculate in their Discussion on whether the observed effects are expected to be maintained after the end of the short-term treatment, or if repeated treatments would be required?
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Author response

> Reviewer \#2:
>
> \[...\] I have a few comments that I believe can be mostly addressed textually, which will improve the clarity of the report, and help improve future reproducibility of analysis.
>
> 1\) The authors mention \"animals\" at both sites but do not specify the sex of the animals. Since a number of age-related phenotypes, including some rapamycin-related phenotypes, have been shown to be sex-dimorphic, it is critical to specify which sex was used for each cohort, at least in the Materials and methods section.

This has now been clarified in the Materials and methods section. All of the mice were female.

> 2\) In this study, rapamycin is delivered through supplementation of diet, and the authors mention that the control chow is reinforced with \"Eudragit\". This reviewer thus assumes that this is to address potential concerns with regular chow diet as a control? It would be extremely helpful to explain the choice of Eudragit (as opposed to normal chow diet) in the main text or Materials and methods.

This has been addressed in Materials and methods section. Eudragit is the encapsulation material used in eRAPA and is a copolymer derived from esters of acrylic and methacrylic acids. Eudragit without rapamycin was thus added to the regular chow at 42 ppm as a vehicle control.

> 3\) In their microbiome analysis, the authors mention significance between old control vs. treated (with regards to Figure 5), and no significance between young and old treated. What about young vs. old? Some of the rapa-induced changes look like they may \"overcorrect\", which should be explicitly discussed in the text as a potential caveat.

We have worked to clarify this. Significant differences were observed between young and old for α diversity (Figure 5A), Firmicutes (Figure 5B) and Proteobacteria (Figure 5B). The potential overcompensation by rapamycin-induced changes such as the trend of apparent lower Bacteroidetes in the rapamycin-treated old vs. young is not statistically supported but could be a real effect. This is now mentioned explicitly in the text.

> 4\) The authors show both microbiome analysis from combined JAX and UW mice in the main figures and a separated analysis in the supplement. Since there are visible specificities in the supplement based on cohort, did the authors have to apply batch-correction of any sort? It would be great to specify analytical parameters, including batch inclusion (or why it was not warranted) in the Materials and methods.

We agree that there were differences by cohort, which is not unexpected. Possible sources of these differences include the facilities and base diet formulations. All samples for microbiome and other analyses were processed in the same lab by the same person who was blinded to the conditions. DNA library preparation and sequencing were conducted in one run. We recognize that there may be species and strain level differences across sites, however at a higher taxonomic level, the differences which were seen in each site independently, did not result in higher variation leading to less significant differences overall. In terms of the applying batch-correction, we thank you for pointing out this concern to us. We concluded that there was no batch effect observed within this data analysis. We have included a Principle Coordinate Analysis (PCoA) using weighted Unifrac distances as Figure 5---figure supplement 4 which shows no clear separation based on either site location and/or group designation. Furthermore, a PERMANOVA analysis using 999 permutations was performed with Bray Curtis calculated distances using the Vegan (2.5-6) Package within the R suite. Results from this PERMANOVA analysis for site location and group designation indicated that no significant differences were observed based on these metadata variables (p = 0.341, ns).

> 5\) Could the authors speculate in their Discussion on whether the observed effects are expected to be maintained after the end of the short-term treatment, or if repeated treatments would be required?

This is definitely an exciting avenue we are currently investigating. We have addressed this in the Discussion section of the main text and noted the published results from Quarles et al. showing that cardiac effects of rapamycin persist for at least 8 weeks following cessation of treatment.

[^1]: Department of Oral & Craniofacial Science, School of Dentistry, University of Missouri-Kansas City, Kansas City, United States.
